Piramal Pharma (NSE:PPLPHARMA) Third Quarter 2023 Results
Key Financial Results
- Net loss: ₹901.8m (flat on 3Q 2022).
- ₹0.76 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Piramal Pharma Earnings Insights
Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.
Performance of the Indian Pharmaceuticals industry.
The company's shares are down 11% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Piramal Pharma has 1 warning sign we think you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:PPLPHARMA
Piramal Pharma
Operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally.
Reasonable growth potential and slightly overvalued.
